Guides
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Botanix Pharmaceuticals.
RELATED STOCKHEAD STORIES
News
Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025
Health & Biotech
Weed Week: Connecticut and Mexico on board cannabis bandwagon, as Rinehart enters the industry
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Botanix soars after pot-up-nose study success
Health & Biotech
Clinical Trials Tracker: 2022 and beyond
Health & Biotech
Botanix collab with UQ confirms antimicrobial potential of CBD
Health & Biotech
Superbugs will kill 22,000 Australians annually by 2040; but these stocks are trying to stop that
News
September Winners Column: Battery metals sentiment has come roaring back
Health & Biotech
Check up: dorsaVi leads ASX health gainers with 60pc rise
Health & Biotech
Weed Week: US cannabis companies wanna take it to the bank
Health & Biotech
This new antimicrobial resistance network could boost Recce, Botanix and Next Science
Health & Biotech
Zelira Therapeutics to launch cannabis-based toothpaste
Health & Biotech
Health Kick Podcast: Botanix is using synthetic cannabinoids to treat acne and other skin conditions
Health & Biotech
Experts: How to position for the next wave in cannabis
Health & Biotech
ASX investors super happy that FDA may approve first new contraceptive pill in 11 years
Health & Biotech
COVID-19 hasn’t hurt cannabis clinical trials … much
News
